Cargando…

Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder

Guanosine (GUO) is a guanine-based purine nucleoside with important trophic functions and promising neuroprotective properties. Although the neuroprotective effects of GUO have been corroborated in cellular models of Parkinson’s disease (PD), its efficacy as an antiparkinsonian agent has not been fu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Massari, Caio M., López-Cano, Marc, Núñez, Fabiana, Fernández-Dueñas, Víctor, Tasca, Carla I., Ciruela, Francisco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632808/ https://www.ncbi.nlm.nih.gov/pubmed/29046640 http://dx.doi.org/10.3389/fphar.2017.00700

Ejemplares similares

PBF509, an Adenosine A(2A) Receptor Antagonist With Efficacy in Rodent Models of Movement Disorders
por: Núñez, Fabiana, et al.
Publicado: (2018)

Guanosine Mechanisms of Action: Toward Molecular Targets
por: Massari, Caio M., et al.
Publicado: (2021)

Adenosine A(1)-A(2A) Receptor-Receptor Interaction: Contribution to Guanosine-Mediated Effects
por: Lanznaster, Débora, et al.
Publicado: (2019)

Striatal Dopamine D(2)-Muscarinic Acetylcholine M(1) Receptor–Receptor Interaction in a Model of Movement Disorders
por: Crans, René A. J., et al.
Publicado: (2020)

Corrigendum: Striatal dopamine D2-muscarinic acetylcholine M1 receptor-receptor interaction in a model of movement disorders
por: Crans, René A. J., et al.
Publicado: (2022)

Investigating the Role of Guanosine on Human Neuroblastoma Cell Differentiation and the Underlying Molecular Mechanisms
por: Belluardo, Natale, et al.
Publicado: (2021)

Exploring Drug-Receptor Interaction Kinetics: Lessons from a Sigma-1 Receptor Transmembrane Biosensor
por: Fernández-Dueñas, Víctor, et al.
Publicado: (2017)

Pridopidine Reverses Phencyclidine-Induced Memory Impairment
por: Sahlholm, Kristoffer, et al.
Publicado: (2018)

c-Abl Inhibition Exerts Symptomatic Antiparkinsonian Effects Through a Striatal Postsynaptic Mechanism
por: Zhou, Yu, et al.
Publicado: (2018)

Extracellular Guanosine 5′-Triphosphate Induces Human Muscle Satellite Cells to Release Exosomes Stuffed With Guanosine
por: Pietrangelo, Tiziana, et al.
Publicado: (2018)

Antipsychotics dosage and antiparkinsonian prescriptions
por: Acquaviva, Eric, et al.
Publicado: (2007)

Neuromodulatory Effects of Guanine-Based Purines in Health and Disease
por: Tasca, Carla I., et al.
Publicado: (2018)

Importance of Nanoparticles for the Delivery of Antiparkinsonian Drugs
por: Silva, Sara, et al.
Publicado: (2021)

Guanosine: a Neuromodulator with Therapeutic Potential in Brain Disorders
por: Lanznaster, Débora, et al.
Publicado: (2016)

Trypanosoma cruzi Phosphomannomutase and Guanosine Diphosphate-Mannose Pyrophosphorylase Ligandability Assessment
por: Zmuda, Filip, et al.
Publicado: (2019)

A STUDY OF PROPHYLACTIC VALUE OF ANTIPARKINSONIAN DRUG
por: Behere, P.B., et al.
Publicado: (1983)

Raising the Guanosine-Based Molecules as Regulators of Excitable Tissues by the Exosomal-Vehiculated Signaling
por: Pietrangelo, Tiziana
Publicado: (2021)

Optical Control of Adenosine-Mediated Pain Modulation
por: Hüll, Katharina, et al.
Publicado: (2021)

Antiparkinsonian Agents in Investigational Polymeric Micro- and Nano-Systems
por: Paccione, Nicola, et al.
Publicado: (2022)

Involvement of Cyclic Guanosine Monophosphate-Dependent Protein Kinase I in Renal Antifibrotic Effects of Serelaxin
por: Wetzl, Veronika, et al.
Publicado: (2016)

The Guanine-Based Purinergic System: The Tale of An Orphan Neuromodulation
por: Di Liberto, Valentina, et al.
Publicado: (2016)

Trends in Antiparkinsonian Medication Use in New Zealand: 1995–2011
por: Pitcher, T. L., et al.
Publicado: (2014)

Parkinson's disease diffusion MRI is not affected by acute antiparkinsonian medication
por: Chung, Jae Woo, et al.
Publicado: (2017)

Antiparkinsonian effects of the "Radiprodil and Tozadenant" combination in MPTP-treated marmosets
por: Michel, Anne, et al.
Publicado: (2017)

Guanosine Prevents Spatial Memory Impairment and Hippocampal Damage Following Amyloid-β(1–42) Administration in Mice
por: Coelho, Victor, et al.
Publicado: (2022)

Guanosine modulates SUMO2/3-ylation in neurons and astrocytes via adenosine receptors
por: Zanella, Camila A., et al.
Publicado: (2020)

The Antiparkinsonian and Antidyskinetic Mechanisms of Mucuna pruriens in the MPTP-Treated Nonhuman Primate
por: Lieu, Christopher A., et al.
Publicado: (2012)

Antiparkinsonian drugs as potent contributors to nocturnal sleep in patients with Parkinson’s disease
por: Taguchi, Soutarou, et al.
Publicado: (2021)

Orthostatic Hypotension and Antiparkinsonian Drugs: A Systematic Review and Meta-analysis
por: Nimmons, Danielle, et al.
Publicado: (2021)

Antiparkinsonian medication masks motor signal progression in de novo patients()
por: Brzezicki, Maksymilian A., et al.
Publicado: (2023)

LUHMES Cells: Phenotype Refinement and Development of an MPP(+)-Based Test System for Screening Antiparkinsonian Drugs
por: Beliakov, Sergei V., et al.
Publicado: (2023)

Editorial: Purinergic Pharmacology
por: Ciruela, Francisco, et al.
Publicado: (2019)

Editorial: Purinergic pharmacology, Volume II
por: Ciruela, Francisco, et al.
Publicado: (2023)

1,5-Benzodiazepin-2(3H)-ones: In Vitro Evaluation as Antiparkinsonian Agents
por: Ortíz de Zárate, Ana, et al.
Publicado: (2021)

Adenosine A(2A)-dopamine D(2) receptor heteromers operate striatal function: impact on Parkinson's disease pharmacotherapeutics
por: Fernández-Dueñas, Víctor, et al.
Publicado: (2018)

Deciphering the Actions of Antiparkinsonian and Antipsychotic Drugs on cAMP/DARPP-32 Signaling
por: Bonito-Oliva, Alessandra, et al.
Publicado: (2011)

Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical Implications
por: Miguelez, Cristina, et al.
Publicado: (2017)

Predictive Factors of Antiparkinsonian Drug Reduction after Subthalamic Stimulation for Parkinson’s Disease
por: SAMURA, Kazuhiro, et al.
Publicado: (2019)

Time until modification of antiparkinsonian therapy in a group of patients from Colombia
por: Valencia-Vásquez, Aníbal, et al.
Publicado: (2023)

Neuropharmacological efficacy of metformin for stroke in rodents: A meta-analysis of preclinical trials
por: Fu, Wenqiao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_13tt7uv05pvjtsvm80rgiag48t